Although some novelbiomarkers, such as urinary liver fatty acid binding protein (L-FABP), urinaryneutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule 1(KIM-1) have been studied for AKI stratification and prediction [5], thecost-effectiveness of using these in clinical practice remains unclear [6].Therefore, predicting AKI with readily calculable markers before tricuspid valvesurgery is essential for identifying high-risk patients and implementingpreventative strategies. Here, FABP1 is linked to acute kidney injury.